Elderly Primary Insomnia Polysomnographic Study

This study has been terminated.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00094666
First received: October 21, 2004
Last updated: January 21, 2010
Last verified: January 2010

October 21, 2004
January 21, 2010
November 2004
March 2007   (final data collection date for primary outcome measure)
Amount of time spent awake and time to fall asleep at night after two days
Not Provided
Complete list of historical versions of study NCT00094666 on ClinicalTrials.gov Archive Site
  • Amount of time spent awake and time to fall asleep at night after 30 days
  • Amount of deep sleep after two days
Not Provided
Not Provided
Not Provided
 
Elderly Primary Insomnia Polysomnographic Study
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, 30-Night Polysomnographic Study of MK0928 in Elderly Patients With Primary Insomnia

The purpose of the study is to test the safety and effectiveness of an Investigational Drug on insomnia in the elderly.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Primary Insomnia
  • Drug: MK0928, gaboxadol / Duration of Treatment - 6 weeks
  • Drug: Comparator: placebo / Duration of Treatment - 6 weeks
Not Provided
Lankford DA, Corser BC, Zheng YP, Li Z, Snavely DB, Lines CR, Deacon S. Effect of gaboxadol on sleep in adult and elderly patients with primary insomnia: results from two randomized, placebo-controlled, 30-night polysomnography studies. Sleep. 2008 Oct 1;31(10):1359-70.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
465
March 2007
March 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Elderly patients with a diagnosis of primary insomnia and in good physical and mental health
Both
65 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00094666
2004_085, MK0928-002
Not Provided
Executive Vice President, Clinical and Quantitative Sciences, Merck Sharp & Dohme Corp
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
January 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP